Abstract: A capacitor and methods for forming the same are provided. The method includes forming a bottom electrode; treating the bottom electrode in an oxygen-containing environment to convert a top layer of the bottom electrode into a buffer layer; forming an insulating layer on the buffer layer; and forming a top electrode over the insulating layer.

Abstract: A capacitor and methods for forming the same are provided. The method includes forming a bottom electrode; treating the bottom electrode in an oxygen-containing environment to convert a top layer of the bottom electrode into a buffer layer; forming an insulating layer on the buffer layer; and forming a top electrode over the insulating layer.

Abstract: Compositions, kits and methods are provided for treating or preventing neurological disorders associated with aberrant silencing of gene expression by reestablishing the gene expression through inhibition of DNA methylation and/or histone deacetylase. The compositions and methods include administering to a patient suffering from the neurological disorder a therapeutically effective amount of a DNA methylation inhibitor, such as decitabine, preferably in combination with an effective amount of a histone deacetylase inhibitor. The compositions, kits and methods can be used to treat or present neurological disorders such as Lou Gehrig's disease, fragile X syndrome, Parkinson's disease and Alzheimer's disease.

Abstract: The present invention achieves the above objects, among others, by providing, in a preferred embodiment a protective laminate for a beverage can, applied before the can components are formed, comprising: at least one layer disposed across substantially an entire upper surface of a top of said beverage can; and said at least one layer having therein at least one score or die-cut line adapted to facilitate manual removal of said at least a portion of said at least one layer before a person consumes contents of said beverage can. A method of manufacturing said protective laminate is also provided.

Abstract: Compositions, kits and methods are provided for treating or preventing neurological disorders associated with aberrant silencing of gene expression by reestablishing the gene expression through inhibition of DNA methylation and/or histone deacetylase. The compositions and methods include administering to a patient suffering from the neurological disorder a therapeutically effective amount of a DNA methylation inhibitor, such as decitabine, preferably in combination with an effective amount of a histone deacetylase inhibitor. The compositions, kits and methods can be used to treat or present neurological disorders such as Lou Gehrig's disease, fragile X syndrome, Parkinson's disease and Alzheimer's disease.

Abstract: Compositions and methods are provided for treating diseases associated with abnormal cell proliferation such as cancer by storing inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent can be an alkylating agent such as a platinum compound, an antibiotic agent, an antimetabolic agent, a retinoid, a hormonal agent, a plant-derived agent, an anti-angiogenesis agent and a biologic agent.

Abstract: A method is provided for treating HIV infection using a combination therapy which includes a compound selected from the group consisting of 20(S)-camptothecin, analog of 20(S)-camptothecin, derivative of 20(S)-camptothecin, precursor of 20(S)-camptothecin and metabolite of 20(S)-camptothecin, in combination with a cocktail of antiretroviral drugs such as nucleoside reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors and integrase inhibitors. The method comprises administering highly active antiretroviral therapy (HAART); and co-administering to the HIV-infected host therapeutically effective amount of a compound selected from the group consisting of 20(S)-camptothecin, analog of 20(S)-camptothecin, derivative of 20(S)-camptothecin, precursor of 20(S)-camptothecin and metabolite of 20(S)-camptothecin.

Abstract: Compositions and methods are provided for treating diseases associated with abnormal cell proliferation such as cancer by restoring inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent is preferably a biologic agent such as an interleukin.

Abstract: Compositions and methods are provided for treating diseases associated with abnormal cell proliferation such as cancer by storing inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent can be an alkylating agent, an antibiotic agent, an antimetabolic agent, a retinoid, a hormonal agent, a plant-derived agent, an anti-angiogenesis agent and a biologic agent such as monoclonal antibody and interferon.

Abstract: Compositions and methods are provided for treating diseases associated with abnormal cell proliferation such as cancer by storing inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent can be an alkylating agent, an antibiotic agent, an antimetabolic agent, a retinoid, a hormonal agent, a plant-derived agent, an anti-angiogenesis agent and a biologic agent such as monoclonal antibody and interferon.

Abstract: The invention comprises a soda can lid which forms a seal with one's upper lip during thereby preventing spillage and eliminating residue. The raised platform area on the lid is connected to the pull-tab area with outwardly sloping walls designed to engage the lips. The platform area is slightly higher than the depth of a circular peripheral groove ranging up to slightly higher than the rim. The lid may also include seal portions extending upwardly from the platform on both sides of the depressed pull-tab area. The invention may be employed on lids either with or without a peripheral groove. Another feature of the invention is a pull-tab with an arch handle and special puncture tip for easier more comfortable use by consumers.

Abstract: Compositions and methods are provided for treating diseases associated with abnormal cell proliferation such as cancer by storing inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent can be an alkylating agent, an antibiotic agent, an antimetabolic agent, a retinoid, a hormonal agent, a plant-derived agent, an anti-angiogenesis agent and a biologic agent such as monoclonal antibody and interferon.

Abstract: A beverage can lid with an easy opening feature comprises a scored lid, having a pull tab affixed to the lid by a rivet and an initial contact point on the lid which is pushed downward as the score line breaks at the puncture point adjacent the rivet. In the invention, the contact point is positioned in close proximity to the rivet to minimize the required lifting force, which is in proportion to the distance between the initial contact point and the rivet. Further, the puncture point is positioned close to the initial contact point so that the lifting force is also reduced. In one embodiment, the scoring radius at the puncture point is quite sharp so that the force required to break the seal at the puncture point is reduced. Also the gap between the puncture point and the end of the scored line is minimized to facilitate opening the lid. Furthermore, the pivot line is moved closer to the contact point to reduce the lifting force.

Abstract: A beverage can lid comprises an outer peripheral groove adjacent the outer rim and an inner concentric groove separated therefrom by a dividing rim which is at a predetermined height relative to the outer rim. A center platform is connected to the dividing rim by walls which slope downwardly from said rim. The central pull tab area is approximately the same height as the height of the inner groove and is connected to the inner dividing rim at one end with an upwardly curving surface. The outer groove which may be shallow and permits entry of a crimping tool to mount the lid on a can is also easily cleaned to provide a sanitary can lid. The inner groove may be blocked in the pouring spout area to facilitate cleaning.

Abstract: A flat end beverage can lid comprises a soda can lid wherein the inner platform is connected with the rim groove. The intent is to facilitate cleaning of the groove and nearby opening hole. The pull tab is located on the inner platform so that it can be readily cleaned by finger. The inner platform extends to the can edge and can be lower than or equal to the rim groove. With this design, it is also possible to use the existing crimping head on the filling line which represents a large cost savings for the filler.

Abstract: This invention comprises a sanitary beverage can lid wherein the center platform of the lid including the pull tab is raised from below the rim of the can as in conventional cans to a position close to or slightly above the rim of the can. The center platform diameter is reduced in diameter to provide additional space from the exterior of the can body to the edge of the platform. The pull tab is positioned in the middle of the center platform so that the end of the pull tab is at the edge of the center platform to facilitate opening of the can. The raised center platform and the lid design prevent an individual's lip from coming in contact with the groove along the edge of the lid where dirt may accumulate. Another feature is the provision of a raised rim on the platform with an interior drain-back slope so that any excess beverage flows back into the can.